氟喹诺酮3种药物治疗下呼吸道感染的药物经济学分析  

Cost-effectiveness analysis of three fluoroquinolones in treatment of lower respiratory tract infections

作　　者：苗佩宏[1] 陈国军[1] 胡忠杰[1] 薛加林[1] 苏静[1] 

机构地区：[1]武警浙江省总队医院,浙江嘉兴314000

出　　处：《中国新药与临床杂志》2009年第12期951-954,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的评价3种常用氟喹诺酮药物治疗下呼吸道感染的成本-效果,指导临床制定合理用药方案。方法将751例下呼吸道感染病人随机分为3组,分别应用莫西沙星400mg(n=254)、加替沙星400mg(n=251)和左氧氟沙星500 mg(n=246)进行静脉滴注治疗,每日1次,连用7～14d,观察临床疗效,并进行成本-效果分析。结果3组总有效率分别为92.4%、85.4%和77.1%,细菌清除率分别为94.5%、89.1%和82.6%,不良反应发生率分别为5.9%、6.2%和8.7%,治疗成本分别为2 404.92、1 080.24和1179.15元;成本-效果比分别为26.01、12.64和15.29。结论应用加替沙星400mg治疗下呼吸道感染是比较合理、经济的用药方案。AIM To evaluate the cost-effectiveness of three fluoroquinolones for the treatment of lower respiratory tract infections, in order to offer a rational drug regimen in clinical practice. METHODS Seven hundred and fifty-one patients with lower tract infections were randomly divided into 3 groups and were given moxifloxacin 400 mg （n = 254）, gatifloxacin 400 mg （n = 251）, and levofloxacin 500 mg （n = 246）, respectively, iv, gtt, for 7 - 14 d. Clinical results were observed and cost-effectiveness analysis was made. RESULTS The total effective rates of 3 groups were 92.4%, 85.4%, and 77.1%, and the germ-clearance rates were 94.5%, 89.1%, and 82.6%, respectively. The incidences for drug adverse reactions were 5.9%, 6.2%, and 8.7%, respectively. The costs of three groups were 2 404.92, 1 080.24, and 1 179.15 yuan and the costeffectiveness ratios were 26.01, 12.64, and 15.29, respectively. CONCLUSION Using gatifloxacin 400 mg is a rational and economical drug project for the treatment of lower respiratory tract infections.

关 键 词：呼吸道感染 经济学 药学 费用-效益分析 莫西沙星 加替沙星 左氧氟沙星 

分 类 号：R978.1[医药卫生—药品] R956[医药卫生—药学]